ESMO 2019 | Onvansertib with cytarabine or decitabine for R/R AML

Amer Zeidan

Amer Zeidan, MBBS, MHS, Yale Cancer Center, New Haven, CT, talks about the polo-like kinase 1 (PLK1) inhibitor onvansertib in combination with low-dose cytarabine or decitabine in R/R acute myeloid leukaemia (AML). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter